Related references
Note: Only part of the references are listed.Simvastatin enhances the efficacy of nilotinib in chronic myeloid leukaemia by post-translational modification and drug transporter modulation
Kartini Asari et al.
ANTI-CANCER DRUGS (2021)
Mitochondria as multifaceted regulators of cell death
Florian J. Bock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Response and Resistance to BCR-ABL1-Targeted Therapies
Theodore P. Braun et al.
CANCER CELL (2020)
Overcoming Wnt-β-catenin dependent anticancer therapy resistance in leukaemia stem cells
John M. Perry et al.
NATURE CELL BIOLOGY (2020)
Effects of Twist1 on drug resistance of chronic myeloid leukemia cells through the PI3K/AKT signaling pathway
Ruilan Yuan et al.
CELLULAR AND MOLECULAR BIOLOGY (2020)
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhe Zhang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia
Raquel Alves et al.
MEDICAL ONCOLOGY (2019)
Mitochondrial protection by simvastatin against angiotensin II-mediated heart failure
Chong-Chao Hsieh et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial
Richard G. Bach et al.
JAMA CARDIOLOGY (2019)
SPAR - a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial
Michael B. Jameson et al.
BMC CANCER (2019)
Simvastatin inhibits sonic hedgehog signaling and stemness features of pancreatic cancer
Yefeng Yin et al.
CANCER LETTERS (2018)
Deptor Is a Novel Target of Wnt/β-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth
Qingding Wang et al.
CANCER RESEARCH (2018)
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
Federico Rossari et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 double-hit B cell lymphoma
Micol Rava et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Inhibition of Siah2 Ubiquitin Ligase by Vitamin K3 Attenuates Chronic Myeloid Leukemia Chemo-Resistance in Hypoxic Microenvironment
Jixian Huang et al.
MEDICAL SCIENCE MONITOR (2018)
Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells
Elodie M. Kuntz et al.
NATURE MEDICINE (2017)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Drug repurposing in cancer
Linda Sleire et al.
PHARMACOLOGICAL RESEARCH (2017)
Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia
Shovik Bandyopadhyay et al.
PLOS ONE (2017)
c-Myc is Required for BRAFV600E-Induced Epigenetic Silencing by H3K27me3 in Tumorigenesis
Yiping Qu et al.
THERANOSTICS (2017)
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Roel Nusse et al.
CELL (2017)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A. Hochhaus et al.
LEUKEMIA (2016)
Mitochondria-Judges and Executioners of Cell Death Sentences
Patrick D. Bhola et al.
MOLECULAR CELL (2016)
Natural course and biology of CML
Bradley Chereda et al.
ANNALS OF HEMATOLOGY (2015)
Simvastatin alleviates cardiac fibrosis induced by infarction via up-regulation of TGF- receptor III expression
Fei Sun et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib
Eliza Glodkowska-Mrowka et al.
EXPERIMENTAL HEMATOLOGY (2014)
PI3K and Bcl-2 Inhibition Primes Glioblastoma Cells to Apoptosis through Downregulation of Mcl-1 and Phospho-BAD
Fresia Pareja et al.
MOLECULAR CANCER RESEARCH (2014)
Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells
Bora Oh et al.
ANTI-CANCER DRUGS (2013)
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling
Bin Zhang et al.
BLOOD (2013)
Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients
Tamer A. Ahmed et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Methyl-β-cyclodextrin induces programmed cell death in chronic myeloid leukemia cells and, combined with imatinib, produces a synergistic downregulation of ERK/SPK1 signaling
Jun Yan et al.
ANTI-CANCER DRUGS (2012)
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
Xuelin Huang et al.
CANCER (2012)
Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML
Florian H. Heidel et al.
CELL STEM CELL (2012)
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia
Oliver Hantschel et al.
NATURE CHEMICAL BIOLOGY (2012)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
P13K-Dependent Upregulation of Mcl-1 by Human Cytomegalovirus Is Mediated by Epidermal Growth Factor Receptor and Inhibits Apoptosis in Short-Lived Monocytes
Gary Chan et al.
JOURNAL OF IMMUNOLOGY (2010)
The Wnt/β-Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML
Yingzi Wang et al.
SCIENCE (2010)
Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway
R. Naughton et al.
LEUKEMIA (2009)
Charting the molecular network of the drug target Bcr-Abl
Marc Brehme et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
In vitro and in vivo study of cell growth inhibition of simvastatin on chronic myelogenous leukemia cells
Yong-Chang Yang et al.
CHEMOTHERAPY (2008)
Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT 5 pathway activation
Ying Wang et al.
BLOOD (2007)
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
A Burchert et al.
LEUKEMIA (2005)
Share Paper
